3 days ago
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results
Metsera Inc. 's shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would allow patients to go from weekly to monthly dosing.
In a small, early-stage trial, Metsera's drug — called MET-233i — helped patients shed up to 8.4% of their weight in 36 days, the company said in a statement. The drug also stayed around in the body longer, meaning it has the potential to be taken less frequently than shots made by Novo Nordisk A/S and Eli Lilly & Co.
